Seeking Alpha

rubicon59

rubicon59
Send Message
View as an RSS Feed
View rubicon59's Comments BY TICKER:
Latest  |  Highest rated
  • Why I'm Buying Up Struggling Retailers [View article]
    I guess all these leases make it kind of hard to close underperforming stores?
    Apr 25, 2015. 10:42 PM | Likes Like |Link to Comment
  • Why I'm Buying Up Struggling Retailers [View article]
    Didn't Circuit City has positive net cash balance in 2008 and generated positive operating cash flows?
    Apr 24, 2015. 02:55 PM | Likes Like |Link to Comment
  • Shun Ho Resources: Undervalued On Multiple Measures Given Severe Holding Company Discount [View article]
    >>Shun Ho Resources holds a 66.94% interest in Hong Kong-listed Shun Ho Technology Holdings Limited.

    I believe Shun Ho Resources holds 50.26% in Shun Ho Technology, not 66.94 (That's according to the latest information on Magnificent;s website.)

    That means SHResources has a 35.7% ownership in Magnificent, valued at 1.12b HKD at the current Magnificent's (undervalued itself) market cap.

    Shun Ho Resources s market cap itself is 0.791b so a 29% undervaluation vs. its public holdings.

    Then there are two additional properties Shun Ho also owns directly - don't know what they are worth off-hand, but got to be additional value to the shareholders over and above Magnificent's ownership.
    Apr 17, 2015. 01:10 PM | Likes Like |Link to Comment
  • Update: Orvana's Q1 Financials Show A Large Capital Position, Low Operating Costs [View article]
    I don't understand why they keep avoiding mentioning their Silver production comparisons which represents ~50% of their revenue and seems to be down disastrously YOY.
    Apr 17, 2015. 12:57 AM | Likes Like |Link to Comment
  • Shun Ho Resources: Undervalued On Multiple Measures Given Severe Holding Company Discount [View article]
    Thanks for a great overview.

    Now, given that the undervaluation hasn't corrected in at least 5 years, may there be some overlooked reason that's holding the valuation down? Will continue to hold it down?
    Apr 16, 2015. 07:27 PM | Likes Like |Link to Comment
  • Fastenal - A Best-Of-Breed Company With An Attractive Risk/Reward Profile [View article]
    For whatever it is worth, $FAST is trading very close to a historically-low PE for the company.
    Apr 2, 2015. 03:06 PM | 2 Likes Like |Link to Comment
  • Priceline: Strong Balance Sheet, Strong Revenue Growth, Fair Valuation [View article]
    Aren't they guiding to single-digit Q1 revenue growth and a EBITDA decline which they also expect to further slow for the rest of the year "due to the size of our business"?

    And that's assuming 1.14 EUR/USD rates, which in reality much worse now.

    A year ago they guided Q1 to 18%% mid-point guidance growth on revenue and EBITDA.

    So the growth, it appears, is grinding to a halt.

    And the trailing PE is still around 25x.

    Am I missing something?
    Apr 1, 2015. 02:37 PM | Likes Like |Link to Comment
  • Why This Reinsurer Is Poised For Continued Outperformance [View article]
    Thank you for a very nice article.

    How would you compare Partner Re with Everest Re?
    Apr 1, 2015. 01:45 AM | Likes Like |Link to Comment
  • A No-Nonsense Projection Of Gilead In 2015 [View article]
    >>I think the pricing was strategic and GILD must have known that ESRX would be negotiating with ABBV.

    If your read the earnings calls and conference transcripts carefully, they admit that the "price war" came as a surprise.
    Mar 31, 2015. 11:39 PM | Likes Like |Link to Comment
  • A No-Nonsense Projection Of Gilead In 2015 [View article]
    Objectively speaking, Gild was surprised by Abbvie's aggressive pricing and had to respond in haste.

    (All this talk about how they strategically priced and then lowered the price, playing "chess", doesn't wash.)

    Even at 46% discount the price of treatment is still super high, so many are nervous about another pricing shock.
    Mar 31, 2015. 06:46 PM | 1 Like Like |Link to Comment
  • Gilead Sciences Faces An Uncertain Future After Patent Loss In India [View article]
    Sadly, this article was apparently written by a value investor who can not afford his medications. :-(
    Mar 31, 2015. 01:00 PM | 1 Like Like |Link to Comment
  • Butler National Is Growing & Generates Half Of Its Market Cap In Free Cash Flow [View article]
    Point well taken. Boy, that huge CapEx jump this quarter was like a bolt out of the blue. Looking also at past history, one has to treat it as the "normal" with this management team. :-(
    Mar 24, 2015. 12:08 PM | Likes Like |Link to Comment
  • A No-Nonsense Projection Of Gilead In 2015 [View article]
    It seems at this rate of prescriptions it will take 10-12 years to cure every HCV patient in the US, and even will likely requires continued price drops year after year to reach the target population.

    After that, the sales will drop precipitously to match the rate of new infections (about 17k/yr).

    One has to be careful with a proper multiple on this kind of business.
    Mar 23, 2015. 06:30 PM | Likes Like |Link to Comment
  • Butler National Is Growing & Generates Half Of Its Market Cap In Free Cash Flow [View article]
    Given the unpredictable capEx, as demonstrated this quarter, I don't think they have the free cash flow you think they have :-(
    Mar 23, 2015. 06:19 PM | Likes Like |Link to Comment
  • A No-Nonsense Projection Of Gilead In 2015 [View article]
    Thanks for the great article.

    With such an enormously-high price umbrella, do you factor in additional entrants into the market collapsing the pricing? BM has a HCV drug in pipeline, perhaps others? 2015 is probably fine, but 3 years out?
    Mar 23, 2015. 01:06 AM | Likes Like |Link to Comment
COMMENTS STATS
1,414 Comments
1,789 Likes